 1. Patients who, during their participation in a previous dupilumab clinical trial, developed a serious adverse event SAE deemed related to dupilumab, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with dupilumab may present an unreasonable risk for the patient. 